Aerovate Therapeutics Faces Delisting Concerns
Ticker: JBIO · Form: 8-K · Filed: Oct 17, 2024 · CIK: 1798749
| Field | Detail |
|---|---|
| Company | Aerovate Therapeutics, INC. (JBIO) |
| Form Type | 8-K |
| Filed Date | Oct 17, 2024 |
| Risk Level | high |
| Pages | 2 |
| Reading Time | 2 min |
| Key Dollar Amounts | $0.0001 |
| Sentiment | bearish |
Sentiment: bearish
Topics: delisting, listing-rule, regulatory
Related Tickers: AVTE
TL;DR
AVTE might get delisted, check their listing status ASAP.
AI Summary
Aerovate Therapeutics, Inc. filed an 8-K on October 17, 2024, reporting a notice of delisting or failure to satisfy a continued listing rule. The company's principal executive offices are located at 930 Winter Street, Suite M-500, Waltham, MA 02451. The filing date for the report is October 11, 2024.
Why It Matters
This filing indicates potential issues with Aerovate Therapeutics' continued listing on an exchange, which could significantly impact its stock value and investor confidence.
Risk Assessment
Risk Level: high — A notice of delisting directly threatens the company's ability to trade on a major exchange, posing a significant risk to its valuation and operations.
Key Players & Entities
- Aerovate Therapeutics, Inc. (company) — Registrant
- October 11, 2024 (date) — Earliest event reported
- October 17, 2024 (date) — Date of report
- 930 Winter Street, Suite M-500, Waltham, Massachusetts 02451 (address) — Principal executive offices
FAQ
What specific rule or standard has Aerovate Therapeutics failed to satisfy, leading to the notice of delisting?
The filing does not specify the exact rule or standard that Aerovate Therapeutics has failed to satisfy, only that a notice of delisting or failure to satisfy a continued listing rule or standard has been issued.
What is the exact date of the earliest event reported in this 8-K filing?
The earliest event reported in this 8-K filing occurred on October 11, 2024.
What is the principal executive office address for Aerovate Therapeutics, Inc.?
The principal executive office address for Aerovate Therapeutics, Inc. is 930 Winter Street, Suite M-500, Waltham, Massachusetts 02451.
What is the Commission File Number for Aerovate Therapeutics, Inc.?
The Commission File Number for Aerovate Therapeutics, Inc. is 001-40544.
What is the Standard Industrial Classification code for Aerovate Therapeutics, Inc.?
The Standard Industrial Classification code for Aerovate Therapeutics, Inc. is 2834, which corresponds to Pharmaceutical Preparations.
Filing Stats: 508 words · 2 min read · ~2 pages · Grade level 10.9 · Accepted 2024-10-17 16:59:05
Key Financial Figures
- $0.0001 — ange on which registered Common Stock, $0.0001 par value per share AVTE The Nasdaq
Filing Documents
- tmb-20241011x8k.htm (8-K) — 41KB
- 0001798749-24-000055.txt ( ) — 162KB
- tmb-20241011.xsd (EX-101.SCH) — 3KB
- tmb-20241011_lab.xml (EX-101.LAB) — 16KB
- tmb-20241011_pre.xml (EX-101.PRE) — 11KB
- tmb-20241011x8k_htm.xml (XML) — 5KB
01 Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing
Item 3.01 Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing. On October 11, 2024, Aerovate Therapeutics, Inc. (the "Company") notified the Nasdaq Global Market ("Nasdaq") that the Company was not currently in compliance with the audit committee composition requirement of Nasdaq Listing Rule 5605(c)(2), due to the Company only having two current members on its audit committee of its board of directors (the "Board") as a result of the resignation of Maha Katabi, Ph.D. on October 6, 2024, which resignation was previously reported. To resolve this noncompliance, on October 17, 2024, the Board approved the appointment of director Habib J. Dable as a member of the Board's audit committee, effective as of October 17, 2024. As a result of this appointment, the Company regained compliance with Nasdaq Listing Rule 5605(c)(2).
01 Financial Statements and Exhibits
Item 9.01 Financial Statements and Exhibits. (d) Exhibits 104 Cover Page Interactive Data File SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Aerovate Therapeutics, Inc. Date: October 17, 2024 By: /s/ George A. Eldridge George A. Eldridge Chief Financial Officer